Re:Pair Genomics
  • Home
  • Product
    • Our Team
    • Timeline
  • News
  • FAQ
    • General Inquiry
    • Promoter Design Inquiry
Re:Pair Genomics

Compact synthetic regulatory elements for gene therapy. ML-designed, synthesis-ready, delivered in days.

Re:Pair Genomics

SpinUP, 3359 Mississauga Rd

Mississauga, Ontario L5L 1C6, Canada

info@repairgenomics.com

Products

  • Platform
  • Pipeline
  • Documents

Company

  • Our Team
  • Timeline
  • News
  • FAQ

Connect

  • General Inquiry
  • Promoter Inquiry
  • Email

© 2026 Re:Pair Genomics Inc.

PrivacyTerms
Our Mission

A 'Mini GPS' forGene Therapy

Our TeamTimeline
The Team

Built by Scientists. Driven by Data.

Executive Team

Shiron Lee

Shiron Lee

Chief Executive Officer and Co-Founder

MSc, MBA cand. Pharmaceutical Sciences

Shiron graduated from University of Toronto with an MSc in Pharmaceutical Sciences. Since her master’s studies, she has gained years of experience in gene therapy research for various neurological disorders, both in academia and industry.

Yosuke Niibori

Yosuke Niibori

Chief Scientific Officer and Co-Founder

PhD

Yosuke is a senior research associate in Pharmaceutical Sciences at the University of Toronto with deep expertise in neuroscience, gene therapy, and bioinformatics.

Luca Hategan

Luca Hategan

Chief Development Officer and Co-Founder

PhD cand. Cells and Systems Biology

Luca is a PhD candidate in Cells and Systems Biology at the University of Toronto and applies machine learning to regulatory element design. He is an expert in Python programming and his passion for bioinformatics led to the development of a machine-learning algorithm to design regulatory elements.

Program Management

Yewon Kim

Yewon Kim

Senior Program Manager

BSc

Yewon studied Economics, Statistics, and Computer Science at the University of Toronto. She brings a multidisciplinary background spanning analytics, growth, and research, with previous experience in growth marketing and machine learning research. At Re:Pair Genomics, she works across strategy, operations, partnerships, and product execution.

Business Development

Abena Saka

Abena Saka

Business Development Manager

BSc, MSc cand.

Abena studied economics at the University of Toronto and is completing graduate studies in banking and finance at Queen Mary University of London. She has previous experience working with a student-led club that later became a registered charity. She is committed to supporting initiatives that better the lives of others.

Alessia Huma

Alessia Huma

Business Development Representative

MSc

Alessia Huma is a Master of Health Informatics candidate at the University of Toronto with a background in Life Sciences. Her experience supporting clinical system implementations and health system strategy initiatives has shaped her passion for using data and technology to enhance patient outcomes, improve healthcare system efficiency, and drive faster innovation in delivering care.

Research and Development

Makaato Serumaga

Makaato Serumaga

Senior Machine Learning Engineer

BSc

Makaato is a Computer Science student at Western University and contributes to Re:Pair's machine learning technology at the biotechnology interface.

Scientific Advisory

Brandon Walters

Brandon Walters

Associate Professor, Department of Psychological & Brain Sciences

Brandon serves as an Assistant Professor at the University of Toronto and contributes psychology expertise to the scientific advisory board.

David Hampson

David Hampson

Professor, Faculty of Pharmacy & Department of Pharmacology & Toxicology

David is a Professor at the University of Toronto with extensive academic and research experience in pharmacology and toxicology.

Iva Zovkic

Iva Zovkic

Associate Professor, Department of Psychological & Brain Sciences

Iva is an Associate Professor at the University of Toronto and serves as a key member of Re:Pair's scientific advisory team.

Business Advisory

Jonathan Paribello

Jonathan Paribello

AI Data and Strategy Analyst (Large Pharma)

Jonathan contributes business-side AI data and strategy perspective from the large pharma sector.